文献速递胸部肿瘤乳腺癌消化系统肿瘤

SHP2抑制可预防多种癌症模型对MEK抑制剂的适应性耐药

SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.
PubMed 文献 · Cancer Discov · 2018-07-25

该研究探讨SHP2抑制剂SHP099联合MEK抑制剂能否克服适应性耐药。体外多种癌细胞系中联合抑制增殖,PTPN11敲低与MEKi效果相似,表达SHP099结合缺陷突变体则耐药。SHP099/曲美替尼在KRAS突变胰腺癌、肺癌、卵巢癌及野生型RAS三阴性乳腺癌模型中高效。

要点

  • SHP2抑制剂SHP099联合MEK抑制剂可抑制多种癌细胞系增殖。
  • SHP099/曲美替尼在KRAS突变胰腺癌、肺癌、卵巢癌及野生型RAS三阴性乳腺癌模型中高效。
  • SHP099抑制具残余GTP酶活性的KRAS突变体激活,并阻断MEKi后的ERK1/2再激活。

核心结论

  • SHP099与MEK抑制剂联合可能在多种恶性肿瘤中具有治疗价值。

研究设计与样本

  • 研究采用体外癌细胞系实验、PTPN11敲低/过表达突变体实验以及异种移植和/或基因工程小鼠模型。

主要发现

  • SHP099联合MEKi在体外抑制多种癌细胞系增殖。
  • PTPN11敲低/MEKi处理效果相似,表达SHP099结合缺陷PTPN11突变体则 confer 耐药,证明SHP099为靶向作用。
  • SHP099/曲美替尼在KRAS突变胰腺、肺、卵巢癌及野生型RAS三阴性乳腺癌模型中高效。
  • SHP099抑制具残余GTP酶活性的KRAS突变体激活,阻止MEKi后SOS/RAS/MEK/ERK1/2再激活,并阻断ERK1/2依赖的转录程序。

临床怎么用

  • 对于MEK抑制剂单药疗效有限的多种恶性肿瘤(如KRAS突变胰腺癌、肺癌、卵巢癌及野生型RAS三阴性乳腺癌),可考虑SHP2抑制剂联合MEK抑制剂的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adaptive resistance to MEK inhibitors (MEKi) typically occurs via induction of genes for different receptor tyrosine kinases (RTK) and/or their ligands, even in tumors of the same histotype, making combination strategies challenging. SHP2 (PTPN11) is required for RAS/ERK pathway activation by most RTKs and might provide a common resistance node. We found that combining the SHP2 inhibitor SHP099 with a MEKi inhibited the proliferation of multiple cancer cell lines in vitro PTPN11 knockdown/MEKi treatment had similar effects, whereas expressing SHP099 binding-defective PTPN11 mutants conferred resistance, demonstrating that SHP099 is on-target. SHP099/trametinib was highly efficacious in xenograft and/or genetically engineered models of KRAS-mutant pancreas, lung, and ovarian cancers and in wild-type RAS-expressing triple-negative breast cancer. SHP099 inhibited activation of KRAS mutants with residual GTPase activity, impeded SOS/RAS/MEK/ERK1/2 reactivation in response to MEKi, and blocked ERK1/2-dependent transcriptional programs. We conclude that SHP099/MEKi combinations could have therapeutic utility in multiple malignancies.Significance: MEK inhibitors show limited efficacy as single agents, in part because of the rapid development of adaptive resistance. We find that SHP2/MEK inhibitor combinations prevent adaptive resistance in multiple cancer models expressing mutant and wild-type KRAS. Cancer Discov; 8(10); 1237-49. ©2018 AACR. See related commentary by Torres-Ayuso and Brognard, p. 1210 This article is highlighted in the In This Issue feature, p. 1195.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Fedele C, Ran H, Diskin B, et al. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discov. 2018. PMID: 30045908. doi:10.1158/2159-8290.CD-18-0444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。